Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This abstract discusses androgenetic alopecia treatments like oral finasteride and topical minoxidil, reporting limited treatment efficacy and no new findings, and emphasizes the psychological impact on patients.

This study found that younger, unmarried individuals under 40, especially women, experienced significant anxiety and depression due to androgenetic alopecia, impacting their psychological well-being and self-perception.

This review discusses the use of microneedling for androgenetic alopecia and finds it promising for enhancing hair density and thickness, especially when combined with other treatments, but notes no standardized protocol exists yet.

This study highlights the challenges adolescents with alopecia areata face, such as increased bullying and emotional difficulties, and suggests that collaborations among dermatologists, psychologists, and educators could help improve their quality of life by reducing stigma and supporting mental wellbeing.

This study reviews female hair loss conditions with a focus on diagnosis and treatment. It highlights female pattern hair loss as the most common form and emphasizes the need for personalized therapy, including topical minoxidil and, when appropriate, antiandrogen treatments.

This article discusses hormonal mechanisms underlying androgenetic alopecia but does not report any new findings; it reviews the roles of dihydrotestosterone and available FDA-approved treatments.

This study investigated the health-related quality of life in individuals with androgenetic alopecia before and after photobiomodulation sessions, but the results of the assessment are not reported in the abstract.

In this study, photobiomodulation treatment using a red low-level laser significantly increased hair density in men with androgenetic alopecia over 10 weeks, yet no additional improvement was observed between the 5-week and 10-week marks.

A new treatment using special microneedles and a nitric oxide-releasing drug could improve hair growth and be more convenient for people with hair loss.

In a mouse model of androgenetic alopecia, this study developed a treatment combining a copper-curcumin nanoparticle oleogel with traditional Gua Sha therapy, which augmented hair regeneration more effectively than minoxidil by improving the follicular microenvironment and regulation of inflammatory responses.

Miniaturized hair follicles in androgenetic alopecia show abnormal mitochondrial activity and damage.

This review discusses treatments for androgenic alopecia, including minoxidil, finasteride, and hormonal therapies with antiandrogens, and reports no new clinical findings.

Topical treatment SM04554 safely promotes hair growth in male baldness.

This preprint reports meaningful improvements in hair density and scalp coverage in an elderly female with androgenetic alopecia treated through an integrative regenerative protocol, involving microneedling and plant-derived exosomes, among other non-pharmacological interventions focusing on cellular senescence pathways.

This study found high patient satisfaction and quality of life in women with androgenetic alopecia using 5% minoxidil, although hair loss still influenced their social life and daily habits.

Smart microneedles improve hair loss treatment by delivering drugs precisely with fewer side effects.

In this retrospective study of 133 pediatric patients, topical minoxidil was generally well tolerated for managing androgenetic alopecia, but close monitoring and adherence to treatment, accounting for hormonal and concurrent conditions, were emphasized for effective care.

This review summarizes existing knowledge on androgenetic alopecia, including its epidemiology, pathophysiology, and management, but presents no new research findings.

This study found that androgenetic alopecia causes significant psychological distress, particularly in women, who exhibit a more negative body image and less adaptive functioning compared to controls.

This study found that androgenetic alopecia had a minor impact on the quality of life among individuals in a Jordanian cohort, potentially due to cultural tolerance of the condition.

Hydrogel microneedles with special nanoparticles and growth factor improve hair growth better than minoxidil for hair loss treatment.

This study developed dissolving microneedles incorporating a new AR degrader for treating androgenetic alopecia, showing that a single application leads to superior hair regeneration compared to daily minoxidil, without systemic toxicity or androgen-related issues.

In this study, researchers observed that patients with androgenetic alopecia show differences in scalp microbial communities compared to the general population, including an increase in Cutibacterium acnes, particularly in males, which may interact with lipid and immune pathways to contribute to hair follicle miniaturization.

This commentary highlights the debate on the role of inflammation and fibrosis in androgenetic alopecia, contrasting various studies' findings without reporting new results.

This study found that androgenetic alopecia in men is associated with significant psychological distress and moderate depression, suggesting a possible link between raised dihydrotestosterone levels and mental health issues.

This study developed a gas-propelled microneedle patch with puerarin/quercetin nanoparticles, which demonstrated improved hair-regenerating effects in an androgenetic alopecia mouse model by increasing drug delivery, alleviating oxidative stress, promoting angiogenesis, and rejuvenating senescent cells.

This study found that alopecia areata significantly impacts emotional and psychological well-being, relationships, and lifestyles, highlighting the need for increased awareness and effective treatments.

This study describes androgenetic alopecia as a common non-scarring hair loss condition primarily influenced by genetic factors and androgen sensitivity, notably impacting psychosocial well-being, especially in females and younger males seeking treatment.

This study evaluated a multimodal treatment involving iontophoresis-assisted growth factor delivery for hair loss, reporting significant reductions in daily hair shedding and high patient satisfaction, particularly in those with telogen effluvium; however, the design suggests these findings should be seen as preliminary.